Systemic AAV9 gene therapy using the synapsin I promoter rescues a mouse model of neuronopathic Gaucher disease but with limited cross-correction potential to astrocytes
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Gaucher disease is caused by mutations in the GBA gene, which encodes for the lysosomal enzyme β-glucocerebrosidase (GCase), resulting in the accumulation of storage material in visceral organs and in some cases the brain of affected patients. While there is a commercially available treatment for the systemic manifestations, neuropathology still remains untreatable. We previously demonstrated that gene therapy represents a feasible therapeutic tool for the treatment of the neuronopathic forms of Gaucher disease (nGD). In order to further enhance the therapeutic affects to the central nervous system, we systemically delivered an adeno-associated virus (AAV) serotype 9 carrying the human GBA gene under control of a neuron-specific promoter to an nGD mouse model. Gene therapy increased the life span of treated animals, rescued the lethal neurodegeneration, normalized the locomotor behavioural defects and ameliorated the visceral pathology. Together, these results provided further indication of gene therapy as a possible effective treatment option for the neuropathic forms of Gaucher disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381 · cited 1×
“Because of its ability to cross the blood-brain barrier following systemic administration (21), AAV9 has been widely used for gene delivery to the central nervous system in several preclinical studies (28) as well as in recent clinical trials for other LSDs (NCT02716246 and NCT03315182) and spinal muscular atrophy (NC…”
MethodThe efficiency of systematic sampling in stereology—reconsidered
GUNDERSEN, H. J. G., JENSEN, E. B. V., KIÊU, K., & NIELSEN, J. (1999) · Journal of Microscopy · doi:10.1046/j.1365-2818.1999.00457.x · Cited by 1,317
Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain
Deverman, B. E., Pravdo, P. L., Simpson, B. P., Kumar, S. R., Chan, K. Y., Banerjee, A., Wu, W.-L., Yang, B., Huber, N., Pasca, S. P., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3440 · Cited by 1,061
McCarty, D., Monahan, P., & Samulski, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301514 · Cited by 735
The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice
Hordeaux, J., Wang, Q., Katz, N., Buza, E. L., Bell, P., & Wilson, J. M. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.01.018 · Cited by 426 · cited 1×
“to rodents; however, as of today the superior characteristics of these new engineered capsids have not translated across different models and species (38).”
BackgroundA Simple Composite Phenotype Scoring System for Evaluating Mouse Models of Cerebellar Ataxia
Guyenet, S. J., Furrer, S. A., Damian, V. M., Baughan, T. D., La Spada, A. R., & Garden, G. A. (2010) · Journal of Visualized Experiments · doi:10.3791/1787 · Cited by 403
Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9
Saraiva, J., Nobre, R. J., & Pereira de Almeida, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.09.011 · Cited by 201 · cited 1×
“Because of its ability to cross the blood-brain barrier following systemic administration (21), AAV9 has been widely used for gene delivery to the central nervous system in several preclinical studies (28) as well as in recent clinical trials for other LSDs (NCT02716246 and NCT03315182) and spinal muscular atrophy (NC…”
MethodTherapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
Hudry, E., & Vandenberghe, L. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.020 · Cited by 77 · cited 1×
“Viral gene therapy offers the unique opportunity to obtain longlived therapeutic effects, particularly for neurological diseases where the treatment needs to reach restricted tissues such as the brain and achieve high levels of transduction (27).”
BackgroundMattar, C. N., Wong, A. M. S., Hoefer, K., Alonso-Ferrero, M. E., Buckley, S. M. K., Howe, S. J., Cooper, J. D., Waddington, S. N., Chan, J. K. Y., & Rahim, A. A. (2015) · The FASEB Journal · doi:10.1096/fj.14-269092 · Cited by 46 · cited 1×
“hGBA vector also carries the WPRE enhancing element downstream of the hGBA transgene, which is known to increase transgene expression of single-stranded AAV vectors when administered intravenously (22).”
BackgroundSelf-citation
Cited by
Daykin, E. C., Ryan, E., & Sidransky, E. (2021) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2021.01.002 · Cited by 77
Delivery technologies for in utero gene therapy
Palanki, R., Peranteau, W. H., & Mitchell, M. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.11.002 · Cited by 64
Allende, M. L., Zhu, H., Kono, M., Hoachlander-Hobby, L. E., Huso, V. L., & Proia, R. L. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109879 · Cited by 37
“Studies in mouse models indicate that while the neuronal deficiency of GBA1 is a primary determinant of CNS pathogenesis, GBA1-deficient microglia may also contribute by influencing the onset and progression of the disease [32, 37, 38].”
Background
Metadata
- Authors
- Massaro, G., Hughes, M. P., Whaler, S. M., Wallom, K.-L., Priestman, D. A., Platt, F. M., Waddington, S. N., & Rahim, A. A.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-01-10
- Volume
- 29
- Issue
- 12
- Pages
- 1933-1949
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W3000397860
- Cited by
- 39
- References
- 9
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.